Guardant Health Announces Preliminary 2024 Financial Results and Regulation FD Disclosure

Details

announced preliminary unaudited financial results for Q4 and the full year 2024, showing total revenue growth of 31% year-over-year. The company also disclosed that it will publish a presentation for the 2025 J.P. Morgan Healthcare Conference on its website. The financial results are preliminary and subject to change. Key highlights include a 29% increase in Q4 revenue, higher clinical and biopharma test volumes, and a preliminary full-year revenue of approximately $737 million.

Items reported

Exhibits (1)

About Guardant Health Inc.

Guardant Health Inc. is an innovative biotechnology company specializing in the development and commercialization of precision oncology diagnostics. This company is recognized for its groundbreaking work in non-invasive cancer detection through liquid biopsy technologies, which involve analyzing circulating tumor DNA in blood samples. Guardant Health’s primary function is to provide oncologists and researchers with critical tools and data to better understand cancer, tailor treatments, and monitor disease progression, potentially improving patient outcomes significantly. Guardant Health operates prominently in the healthcare and biotechnology sector, significantly impacting fields such as cancer research and personalized medicine. Their products and services are vital for facilitating early detection of cancer, identifying treatment options, and offering companion diagnostics for pharmaceutical developments. In the financial market, Guardant Health represents an important player within the precision medicine landscape, influencing investment within the biotechnology and healthcare sectors. Founded in 2012 and headquartered in Redwood City, California, the company continues to expand its portfolio and advance its technologies, playing a pivotal role in the fight against cancer at a global level.